Biogen Inc. (BIIB) has seen an evolution of financial and medical developments in recent years. It has been evaluated as a cheap Healthcare stock to purchase heading into 2025, despite a recent decline by 6.4% in 4 weeks. The executive Vice President and CFO, Michael McDonnell is set to retire in February 2025. Biogen has taken significant steps forward in the treatment of Alzheimer's disease, including collaborations with Beckman Coulter and Fujirebio. Positive topline results have been observed in their study of a higher dose regimen of Nusinersen for SMA. The company's late-stage pipeline is flourishing visibly; acquisition of Human Immunology Biosciences expanded their immunology portfolio. Their drug for early Alzheimer's (lecanemab), is now approved for use in Great Britain, Israel and China. However, investors have lost about 32% over the past three years due to fluctuations in stock valuation. Despite this, profit predictions are on the rise due to traction gained by lecanemab. Several new data and research collaborations were also announced, aimed at discovering novel treatments for Alzheimer's, rare and immunological diseases.
Biogen BIIB News Analytics from Wed, 31 Jan 2024 08:00:00 GMT to Sat, 28 Dec 2024 21:49:55 GMT -
Rating 5
- Innovation 3
- Rumor -2
